Last reviewed · How we verify
Placebo (for Tamoxifen)
A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and psychophysiological processes.
A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and psychophysiological processes. Used for Control arm in Tamoxifen clinical trial.
At a glance
| Generic name | Placebo (for Tamoxifen) |
|---|---|
| Sponsor | Oregon Health and Science University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials. In this case, it serves as a comparator arm in a Tamoxifen study, allowing researchers to distinguish the drug's true pharmacological effects from placebo response. Any observed benefits in the placebo group result from expectation, conditioning, and natural disease progression rather than active drug mechanism.
Approved indications
- Control arm in Tamoxifen clinical trial
Common side effects
Key clinical trials
- New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia (PHASE2)
- Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy (PHASE3)
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (PHASE3)
- FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy (PHASE2)
- Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (PHASE2)
- Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Tamoxifen) CI brief — competitive landscape report
- Placebo (for Tamoxifen) updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI